CTOs on the Move

Hercules Pharmaceuticals

www.herculesrx.com

 
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.herculesrx.com
  • 27, Seaview Boulevard
    Port Washington, NY USA 11050
  • Phone: 800.815.5800

Executives

Name Title Contact Details

Similar Companies

ASP Global

We help you reach your savings targets and your patient experience goals by designing and delivering supplies and patient care products.

Low T Center

Low T Center, mens health clinic, offers treatment for low t levels with testosterone replacement therapy, (hormone replacement), and sleep apnea .

Fovioptics (Main)

Fovioptics (Main) is a Santa Clara, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Teligent

Teligent is a specialty generic pharmaceutical company. Our mission is to be a leading player in the specialty generic prescription drug market. Called TICO, our strategy is focused on developing and selling pharmaceutical products in the Topical, Injectable, Complex and Ophthalmic markets. Based in Buena, New Jersey, we have approximately 200 employees working at our 33,000 square-foot manufacturing and R&D complex, as well as in our Canada and Estonia operations. We are currently expanding our New Jersey site to include a sterile injectable, isolator-based manufacturing suite and an expanded footprint for the production of our topical products. There are three pillars that shape our company. First, we are driven by impactful science. Second, we accept no middle ground when it comes to product quality. Finally, we believe in fostering a career of craftsmanship, where our people can become experts in their trade. The spirit of our culture is to work hard, and be nice to people.

Silence Therapeutics

Our 20-plus years of RNAi experience together with our validated mRNAi GOLD™ platform make us a partner of choice for pharmaceutical companies looking to access the benefits of the siRNA and add this revolutionary modality to their discovery pipeline. As pioneers in the design and development of siRNAs (short interfering RNAs), Silence Therapeutics is advancing a new generation of medicines to potentially address the needs of patients who have limited or inadequate treatment options. Our mission is to use our technology to create a new generation of therapeutics which can improve outcomes for patients and, in the process, build shareholder value. We are developing a deep pipeline of innovative siRNAs based on our mRNAi GOLD™ platform for diseases with a genetic basis. The depth and versatility of our liver-targeting technology gives us the opportunity to address a wide range of conditions in virtually any therapeutic area.